No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 24
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Sana Biotechnology, Inc. (SANA) stock was $2.77 as of Oct 6, 2026, 1:45 PM EDT, down 3.80% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -27.2% · 3-year avg -8.6%/yr · 5-year avg -32.3%/yr
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells.
Biotechnology · Seattle, WA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.15
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.13
vs Estimate
$-0.12
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SANA | $771.06M | $2.77 | -3.80% | -27.16% | -32.33% | N/A | N/A |
| 2LXRX | $768.46M | $1.73 | -0.57% | +23.28% | -18.54% | -21.03% | vs SANA |
| 3APMD | $767.19M | $19.27 | -11.43% | N/A | N/A | N/A | vs SANA |
| 4MLAB | $765.23M | $136.75 | -3.85% | +94.75% | -13.52% | +2.29% | vs SANA |
| 5ATTO | $761.20M | $17.69 | -1.69% | N/A | N/A | N/A | vs SANA |
| 6GYRE | $784.66M | $7.04 | -4.24% | +0.14% | -0.34% | -14.92% | vs SANA |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 7 analysts
Average Price Target
$8.43
+204.2% upside
Low
$6.00
Current
$2.77
High
$12.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.23 | $-0.15 | $-0.10 | 5 |
| Quarter ending Dec 2026 | $-0.23 | $-0.17 | $-0.11 | 4 |
| Quarter ending Mar 2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Quarter ending Jun 2027 | $-0.14 | $-0.14 | $-0.14 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.76 | $-0.69 | $-0.57 | 6 |
| FY 2027 | $-0.78 | $-0.59 | $-0.42 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $6.95M | $6.95M | $6.95M | 6 |
